Biotech Values

[biopearl]

Re Gern: Scarlett made the point the some patients were advanced enough in their disease to have already undergone splenectomies prior to imetelstat treatment or did not have much in the way of constitutional symptoms when treatment began, so these could not be used as endpoints. My read of the study (criticized harshly by some on the board) is that this is about some fundamental aspects of MF--blood counts, molecular response and reversal of BM fibrosis--everything else as the sages said "is commentary." I don't think the yard stick of JAK2 inhibitors can be used to measure the responses being reported with imetelstat. I do think the company will "unparse" on Monday. Regards, bp